Title: A cross-sectional analysis of self-reported needs and health service utilization among transgender women in Lima, Peru

Authors: Elizabeth A. Carosella, MPH[1*]; Leyla Huerta[2]; Jerome T. Galea, PhD, MSW[3,4]; Leonid Lecca, MD, MSc[3,5]; Karen Ramos[5]; Giulianna Hernandez[5]; Molly F. Franke, ScD[3◊]; Jesús Peinado, MD, MSc[5,6 ◊]

[1] Department of Epidemiology and Department of Biostatistics, Harvard T.H. Chan School of Public Health; Boston, Massachusetts, United States
[2] Feminas de Lima; Lima, Peru
[3] Department of Global Health and Social Medicine, Harvard Medical School; Boston, Massachusetts, United States
[4] University of South Florida, School of Social Work; Tampa, Florida, United States
[5] Partners In Health/Socios En Salud Sucursal Peru; Lima, Peru
[6] School of Medicine, Faculty of Health Sciences, Peruvian University of Applied Sciences; Lima, Peru
*Current address: Mathematica Policy Research; Cambridge, Massachusetts, United States

◊ Contributed equally

Corresponding author contact information: Jesús Peinado, MD MSc, Socios En Salud Sucursal Peru, Puno 279 Street, Lima Downtown, Lima, 150101, Peru, +51999000586, jpeinado_ses@pih.org

Key words: Peru, Transgender women, Transgender health, HIV/AIDS, PrEP, tuberculosis

Word counts:

Abstract: 244 words

Main text: 3,716

Tables: 3

Figures: 0

Supplementary materials: 0

Abstract

Purpose: Globally, transgender women (TGW) experience wide-ranging barriers to health and care, with disproportionately high risks of infectious and chronic diseases. Despite these vulnerabilities, research on access to care for transgender populations in low- and middle-income countries is extremely limited. Furthermore, existing studies have primarily focused on human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), with less emphasis on TGW's broader health needs. This study analyzed patterns of morbidity and health service uptake among TGW in Lima, Peru. The purpose was to better understand health outreach and service needs to inform targeting and design of future community-level interventions.

Methods: This cross-sectional study surveyed a convenience sample of 301 TGW in metropolitan Lima, Peru. Data was collected between September – October 2020. This paper provides descriptive statistics and results of bivariate and multivariable regression models.

Results: Health coverage and access to care were suboptimal. Less education and older age were positively associated with illness and HIV and tuberculosis (TB) testing. Gender identity sub-group (i.e., woman, trans or transgender, transsexual, "*transformista*," "*travesti*," and other) was associated with HIV testing and pre-exposure prophylaxis (PrEP) usage. Both awareness of and interest in PrEP were low, as was usage among those who were interested in taking PrEP.

Conclusion: Future public health efforts should be tailored to meet the diverse needs of TGW, expand TB testing, bridge the gap between PrEP interest and use, and increase insurance coverage and access to trans-friendly services to promote improved health outcomes.

Introduction

Globally, transgender women (TGW) —individuals born as or assigned male sex at birth who

identify as female or another gender that is not male—experience severe and wide-ranging structural,

cultural, and interpersonal barriers to access to and utilization of healthcare.[1] These barriers increase their

risk of numerous poor health outcomes, including human immunodeficiency virus infection and acquired

immune deficiency syndrome (HIV/AIDS), substance use disorders, violence and injury, mental illness,

and other chronic diseases.[2–4]

Through these challenges exist in many parts of the world, Latin America is one of the world's

least hospitable places for TGW, [5] with pervasive transphobia, cultural conservativism, and *machismo,*[6,7]

a concept of masculinity characterized by traditional beliefs about gender roles and men's superior

societal status. Despite some recent regulatory improvements, most Latin American countries deny TGW

legal recognition of their gender identity, access to gender-affirming care, and numerous other benefits

and protections.[8] Discrimination is widespread, including at health facilities, where providers may refuse

treatment or give inadequate care to TGW.[9] For TGW who migrate to cities where they have limited

support,[10] sex work is often one of the only livelihood options available,[11,12] increasing the risks for STIs,

including HIV/AIDS, and other infectious diseases.[13]

The health needs and healthcare utilization of TGW remain understudied.[4,14] Less than 0.01% of

PubMed articles focus on transgender populations, with most articles from the US.[15] Data are scarce, in

part, because it has historically been common to combine transgender populations with men-who-have-

sex-with-men (MSM).[16–18] Although pre-exposure prophylaxis (PrEP) is one of the greatest advances in

HIV prevention, in Peru current levels of PrEP awareness, interest, and utilization among TGW are not

well understood. The ImPrEP demonstration study[19] identified several barriers, including long wait times

at dispensary sites due to a lack of doctors needed to prescribe PrEP, lack of information, concern about

adverse reactions, and logistical issues that impede PrEP delivery at patient appointments. There is also a

lack of data on tuberculosis (TB) risk, despite Peru having the second highest TB incidence in the western

hemisphere and being the only Latin American country on the WHO's top 30 high multidrug resistant TB

(MDR-TB) burden countries.[20] We are not aware of TB incidence data among Peruvian TGW; however,

research elsewhere suggests a significant risk.[21]

Another limitation to existing research with TGW is that it largely considers a single,

homogenous group. However, there are diverse gender identities within the broader transgender

community that impact social perceptions, lived experiences, and behavior trends.[19] In Peru, commonly

used terminology ascribes different characteristics: "*travesti*," refers to TGW who "utilize female dress

full time;" "*transformistas*" alternate between masculine and feminine appearance;[22] while the umbrella

term "trans" is not consistently applied in the literature or in practice.[4] Nuanced quantitative research on

sub-groups could improve targeting of interventions to those at higher risk of poor health or barriers to

care.

To inform future clinical and public health outreach and interventions by the nongovernmental

organizations Socios En Salud [Partners In Health] and Feminas de Lima, we explored healthcare needs,

including health coverage and utilization of HIV and TB testing and gender affirming care, and associated

factors, in TGW in Lima, Peru.

Methods

Study setting: The exact size of the TGW population in Peru is unknown; there are no national

population-level data on transgender health. Research from the US[23,24] estimates transgender identity

prevalence at 0.3% to 0.5%, which, if applied to Peru, suggests that the transgender population overall

could be close to 165,000 people. HIV prevalence among Peruvian TGW is 31.8%, in contrast to 10%

among MSM,[25] and 0.3% prevalence in the general population.[26] Yet, testing among TGW remains low.[27]

In 2016, Peru's Ministry of Health (MINSA) established a resolution[28] for STI and HIV infection

prevention and control among TGW. MINSA guidelines recommend HIV and syphilis testing on a

quarterly basis and outline hepatitis B vaccination, distribution of condoms and lubricant, and the process

for hormone therapy for TGW. Only surgeons with specialized training involving transgender patients

may administer hormone therapy. In practice, few public facilities provide these services and most

transgender-sensitive and gender-affirming healthcare available is accessed through the private sector[26] or

in conjunction with participation in clinical research, especially HIV clinical trials.[29]

Peru's food and drug administration, *Dirección General de Medicamentos, Insumos y Drogas*

(DIGEMID), approved pre-exposure prophylaxis (PrEP) in 2017 following its participation in the

landmark iPrEx trial. However, there is a continued lack of national policies and guidelines, which

contributes to limited uptake. Mostly, PrEP is accessible to TGW through participation in research, such

as the MINSA-sponsored ImPrEP demonstration project[30] or buying it over the counter.[31] The

organization PrEP Watch estimates that there are only 2,500 – 3,000 PrEP users in Peru as of October

2021.[32]

Study design and population: We conducted an exploratory cross-sectional study of socio-

demographic characteristics and health service utilization among Peruvian TGW in the capital city of

Lima, with data collected between September – October 2020. The study population was drawn using a

convenience sampling approach, targeting TGW recruited from 21 of 43 districts in Lima. All

participants were members of Feminas de Lima, a non-governmental organization comprised of and led

by TGW, which is dedicated to transgender health and advocacy.[33]

Participants and recruitment: Feminas members (N = 311), all of whom identify as part of the

TGW community, in participating districts were contacted by phone and invited to participate.

Respondents were at least 18 years old, identified as TGW, and resided in a district of metropolitan Lima.

Participants were excluded if they lacked capacity to consent or complete the survey or reported active

SARS-CoV-2 symptoms. Peer enumerators - TGW affiliated with Feminas – made in-person visits to

each respondent, confirmed fulfillment of criteria, and administered the survey by reading the questions

aloud. Ten people either refused to participate or did not respond to phone calls. A total of 301 TGW

responded, 46.5% born in Lima and 53.5% originally from other departments. Each respondent gave

informed consent.

Data collection: The survey instrument was developed in Spanish. It was piloted with four

Feminas members to test comprehension, time to completion, and overall ease of use before being

administered among the full survey sample. Peer enumerators read questions aloud in Spanish and

entered responses into a digital form, which staff later uploaded to a central database, which alerted the

enumerator if any question was not answered. Surveys took approximately 40 minutes to complete, and

there was no missing data.

Study Measures: Survey questions were based on a prior questionnaire developed by Socios En

Salud researchers and tested with Feminas in 2019. Data included demographics, including department of

origin (i.e., birthplace, categorized as Lima or outside Lima); age; current residence (house, apartment,

room, hostel, no fixed address); highest level of education, and current employment (yes/no). Those

currently working could select multiple options for employment type (working for a business, working

independently, and sex work). To capture gender identity, we asked participants "how do you define

yourself" with response options (Table 1) defined by Feminas based on their knowledge of the TGW

community as well as an option to select "other." The survey included binary response options to the

questions "do you suffer from an illness?"; "do you attend a health facility?" and, if so, public or private;

"have you heard of PrEP?" and, if so, "would you be interested in PrEP?" and "have you ever taken

PrEP?". There were multiple-choice questions for "how frequently do you get checkups at your health

facility?", "do you have health insurance?", "have you ever been tested for HIV?", and "have you ever

been tested for TB?" with responses reported in Table 2.

Ethical considerations: The research protocol and informed consent were approved by the

Institutional Review Board of the Peru National Health Institute of Health in June 2020 (OEE-002-20).

Participants provided informed consent and we provided them a kit consisting of a face mask, hand

sanitizer, condoms, lubricants, and information on where they could access free HIV testing, but no other

incentives. The research was completed in accordance with the Declaration of Helsinki as revised in

2013.

Statistical Analysis: Data were analyzed in Stata 17 (StataCorp LP, College Station, TX, USA).

Sample characteristics were described by frequencies and percentages. Age was examined as a categorical

variable (i.e., younger than 27 years, 27 – 35, and 36 and older), with upper and lower thresholds

corresponding to the highest and lowest quartiles. For gender identity analyses, the self-reported

"transgender" category was pooled with "trans," as Feminas leadership confirmed that these terms are

understood synonymously. We evaluated whether these characteristics were associated with binary

outcomes for insurance coverage, self-reported illness, regular clinic attendance, TB and HIV testing, and

PrEP usage.

Bivariable Poisson regression models with robust error variance were fit to calculate unadjusted

prevalence ratios (PRs) and 95% confidence intervals (CIs) for risk factors and six outcome measures:

being uninsured, self-reported illness, clinic attendance, TB testing, HIV testing, and PrEP use. The

potential risk factors for these outcomes included age group, education level, department of origin,

current employment, sex work, and gender identity subgroup. These factors were selected because they

were hypothesized to be potential markers of suboptimal health and/or health access within the TGW

community in Peru, thereby serving as a means to identify individuals who could benefit from additional

support. To calculate adjusted prevalence ratios (aPRs), we then fit a multivariable model for each

outcome in which we included all factors of interest (i.e., each factor was adjusted for the others). We

largely avoid reference to statistical significance and emphasize CIs to allow analysis of the direction and

strength of observed effects.

Results

Descriptive Statistics

Socio-demographics

Socio-demographic characteristics among 301 respondents are shown in Table 1. Mean age was

32.4 years (range 18-64). 36.5% had completed higher than secondary education. The majority were

currently working (79.1%). Sex work was the most common livelihood (48.2%). More than half were

born outside Lima (53.5%). Trans or transgender (58.5%) was the most common gender identity,

followed by women (15.3%), *transformistas* (9.0%), transsexuals (8.3%), and *travestis* (7.0%).

Healthcare utilization

Insurance: As described in Table 2**,** 35.2% of respondents were uninsured. Subsidized public

health insurance *Seguro Integral de Salud* (SIS) was the most common (53.8%) insurance option,

followed by the contributory public social health insurance (EsSalud) (7%), private insurance (3.7%), and

supplementary private insurance (EPS) (0.3%).

Clinic Attendance: A high proportion of TGW regularly attended a health clinic (80.1%), with

most using public facilities (83.4%).

HIV and TB: Most participants reported prior testing for HIV (96.3%), though testing frequency

within 12-months was lower (57.5%). A considerable percentage (36.5%) had never been evaluated for

TB. Among the total sample, 60.1% were aware of PrEP, of whom 55.8% expressed interest in initiating

it (33.6% of the sample); 21.0% (12.6% of the sample) reported they had ever used PrEP.

Gender-affirming Care: Respondents commonly reported access to gender affirming procedures

(91.4%); among these, most reported non-surgical procedures.

Factors associated with health care usage

Insurance: As shown in Table 3, older TGW aged 27 – 35 were 38% less likely than TGW under

age 27 to be uninsured (aPR for 27 – 35 years = 0.62, 95% CI: 0.43, 0.90). The trend was also observed

for TGW over age 35, (aPR for > 35 years = 0.67, 95% CI: 0.43, 1.04) though the CI included 1.

Compared with respondents who had higher than secondary education, TGW with primary education or

less were 77% more likely to be uninsured (aPR = 1.77, 95% CI: 1.04, 3.03).

Illness: TGW with primary education or less had higher prevalence of self-reported illness (aPR

= 2.61, 95% CI: 1.07, 6.40). Employed TGW had a lower prevalence of self-reported illness (aPR = 0.48,

95% CI: 0.27, 0.85). Older TGW were more likely to report illness though CIs for these estimates were

wider and included one (Table 3).

Clinic Attendance: Older TGW were more likely to report clinic attendance (aPR for 27-35 years

= 1.08, 95% CI: 0.91, 1.27; aPR for > 35 years = 1.15, 95% CI: 0.97, 1.36). Employed TGW had lower

clinic attendance (aPR = 0.88, 95% CI: 0.76, 1.02). In an a posteriori analysis, we examined whether sex

work could moderate the relationship between employment and illness or clinic attendance but did not

find statistical evidence of this (p = 0.31 for interaction).

TB Testing: Older TGW were less likely to have ever had a TB test (aPR for 27 – 35 years = 0.57,

95% CI: 0.31, 1.05; aPR for > 35 years = 0.27, 95% CI: 0.10, 0.72). This was also true of those with

lower levels of education (aPR for primary education or less = 0.29, 95% CI: 0.05, 1.89; aPR for

secondary education = 0.61, 95% CI: 0.35, 1.06) though CIs included 1. Employment did not appear to

impact TB testing (aPR = 1.01, 95% CI: 0.47, 2.18).

HIV Testing: Older TGW, particularly those over age 35, were less likely to have ever had an

HIV test (aPR for those > 35 years = 0.68, 95% CI: 0.45, 1.01). Older age also was inversely associated

with sex work (aPR for 27 – 35 years = 0.69, 95% CI: 0.55, 0.87; aPR for those > 35 years = 0.44, 95%

CI: 0.31, 0.64). As with TB, lower levels of education were associated with lower likelihood of HIV

testing (aPR for primary education or less = 0.71, 95% CI: 0.40, 1.24; aPR for secondary education =

0.70, 95% CI: 0.54, 0.90). Again, employment did not appear to be associated with HIV testing (aPR =

0.95, 95% CI: 0.66, 1.37). TGW who identified as women were more likely to test for HIV (aPR = 1.49,

95% CI: 1.16, 1.91).

PrEP and gender affirming care: Compared to those who identified as trans or transgender TGW

who identified as women were more likely to use PrEP (aPR = 2.36, 95% CI: 1.15, 4.80) and report

having had surgical procedures: PR: 1.73 (0.92, 3.24). Those who indicated their gender identity as

"other" were also more likely to use PrEP (aPR = 5.64, 95% CI: 2.75, 11.58). We did not find strong

evidence that any other factors were associated with PrEP use or gender affirming care.

Discussion

This study identified a diverse population with varying health needs and service utilization

patterns. Overall, TGW had suboptimal levels of health coverage and care, with less education and older

age as important risk factors for many outcomes. In the first study to quantitatively examine health

utilization by gender identity subgroups in Peru, we also found that TGW who identified as women had

higher HIV testing and PrEP uptake compared to those who identified as trans or transgender.

Nearly one in five respondents reported that they did not receive facility-based healthcare. This

may be due to a combination of factors that contribute to poor linkages to and retention in healthcare.[34]

Over one-third of our sample did not have insurance of any kind, with the lowest levels of insurance

among younger and less educated TGW. In Peru, national ID cards typically do not reflect TGW's true

gender identity,[35] which can obstruct administrative processes. Many TGW either lack ID cards entirely

or do not use them for fear of being subjected to ridicule or abuse, including in health centers.[35] Because

national ID cards are required for Peruvians to enroll in the SIS, despite regulatory changes in recent

years to loosen restrictions for changing gender on national IDs, this remains a barrier to healthcare

access.

The lack of differentiated services or trans-friendly spaces within Peru's health system is likely

another important barrier.[26] Gender-affirming healthcare is rarely provided in public facilities and we

found a high prevalence of non-surgical gender affirming care practices- mainly, hormone injections and

silicone implants, which are often obtained outside the health system.[10,11,22] Previous studies found that

TGW may self-administer treatments or rely on medically-unqualified acquaintances.[11,22] Medical

providers and staff may lack training and cultural competency to provide quality services to TGW.[36,37]

The expectation of hostile, discriminatory, or substandard treatment may deter even those who have

public insurance from seeking facility-based care. To date most scholarship has focused on patient

perspectives, and we call for more research on providers' knowledge, attitudes, and other supply-side

barriers to care facing TGW.

Though HIV testing was generally high, older and less educated TGW were less likely to be

tested. Older TGW may have had less exposure or access to preventive testing, free anti-retroviral

treatment, and informational and anti-stigma campaigns, which have become more common over time.

Moreover, older age was negatively associated with sex work. We hypothesize that less frequent sex work

among older women may reduce older TGW's HIV risk or risk perception, leading them to test less

frequently.

In contrast with HIV testing, TB testing was low with over one in three TGW never tested. Given

Peru's high national TB burden, TGW may face a disproportionately high risk of infection due to HIV

and a tendency to cluster in communal homes. Stigma and discrimination may limit access to housing:

nearly half of participants lived in shared housing or hostels in the few districts where they can secure

housing.[33,38]

Given that this study's overarching goal was to help inform and appropriately target future health

outreach and interventions, we assessed patterns among different gender identity subgroups to pinpoint

those that may be most in need of services. This analysis builds on prior qualitative research about the

varied experiences of different gender identity subgroups within Peru's TGW community and existing

quantitative research with TGW that largely assesses them as a homogenous group. We found that TGW

who identify as women were 49% more likely to have been tested for HIV compared to those who

identify as transgender.

A sub-analysis found that women had nearly twice the prevalence of surgical procedures

compared to those who identified as trans or transgender. Together with findings on testing rates, this

might reflect that having a physical appearance that aligns with a traditional binary gender reduces

friction in TGWs' interaction with the health system and facilitates access. More qualitative research on

how different gender identities impact the testing and broader healthcare utilization could better

illuminate this finding. Note that this research was exclusive to TGW, and there is little research available

on Peruvian transgender men or non-binary populations.

About two in five TGW (39.9%) had never heard of PrEP, and there was a large gap between

those who expressed interest in PrEP (55.8%) and those who reported ever using it (21.0%). Overall,

prevalence of PrEP usage was just 12.6%. Prior research highlights several barriers: limited perceived

benefits, clinicians' disregard of side effects, anticipated out-of-pocket costs, and concerns that PrEP

would disincentivize condom usage among PrEP users.[29,39] Mistrust of medical institutions, doubts about

safety and efficacy, suspicion of actors offering free PrEP, and feelings of exploitation in the face of

persistent barriers to PrEP access outside of research environments are also common.[29] Further research

among those who report interest but not uptake could disentangle supply- versus demand-side factors and

inform strategies to increase PrEP knowledge and demand. Looking forward, the US FDA approved long-

acting injectable PrEP- cabotegravir (CAB - LA)[40,41] in December 2021,[42] which may reduce barriers to

dosing, adherence, and stigma related to daily oral medication.

At the time of study, authors were unaware of any community-level interventions that address

broader health issues among Lima's TGW. Existing services tailored for TGW have been secured for

national HIV surveillance and HIV prevention clinical trials, as well as Ministry of Health screenings,

which require going to a health facility. Along with existing HIV programs, there may be opportunities to

build on COVID-19 testing strategies and infrastructure that focus on extending health services that reach

TGW where they are.

Limitations

This was an exploratory analysis aiming to identify subgroups of TGW who could be prioritized

for interventions to improve access to care. We did not adjust for multiple comparisons because the goal

of our analysis was not to identify singular statistically significant associations but rather to identify

meaningful patterns of healthcare utilization. There is potential for selection bias; however, we expect

that this is limited given Feminas' extensive network and the high participation rate. The study relied on

self-reporting, which could introduce bias, the direction of which may be difficult to predict. Furthermore,

while a strength of this study was the participation of 301 TGW respondents, small sample sizes may

influence some results such as those for gender identity sub-groups where, for example, just six

participants reported "other" gender identities (see Table 3).

Finally, meanings associated with gender identity labels are evolving; certain terms, like

"transsexual," become less commonly used and others like "trans" begin to subsume previous catch-all

terms like "*travesti.*" This may limit interpretation or generalizability of associations with specific gender

identity. The use of the Feminas peer promoter network to identify study participants and implement the

survey assured that respondents' gender identities fell within the umbrella of TGW. However, we

recognize that identity is often fluid and part of a transition process, and that respondents may have been

at different stages. Future surveys may be more inclusive by incorporating additional options and

utilizing a "check all that apply" approach to gender identity collection.

Conclusion

We identified gaps in health coverage and services among Peruvian TGW. Outreach and

interventions should aim to expand insurance coverage and access to trans-friendly services for TGW

who do not seek facility-based care, particularly younger TGW. While HIV testing rates were high, PrEP

uptake remains suboptimal. Further efforts are needed to bridge the gap between interest and usage.

Finally, TB research and services should be prioritized, given the paucity of data and the potential for this

population to be disproportionately affected.

Acknowledgements

We are grateful to the study participants for sharing their experiences. Socios En Salud Peru

developed the survey, collected the data, and analyzed findings. Feminas co-designed the survey, supplied

peer community health workers, and contributed to the analysis.

Authorship Contribution Statement

Elizabeth A. Carosella: Methodology, data curation, formal analysis, writing – original draft. **Leyla**

Huerta: Conceptualization, investigation, resources, validation. **Jerome T. Galea**: writing – review &

editing. **Leonid Lecca**: Conceptualization, resources. **Karen Ramos**: Investigation, supervision.

Giulianna Hernandez: Investigation, supervision. **Molly F. Franke**: Conceptualization, methodology,

validation, writing – review & editing**. Jesus Peinado**: Conceptualization, methodology, validation,

supervision, writing – review & editing.

Author Disclosure Statement

All authors declare no conflict of interest.

Funding Statement

This work was conducted by the Socios En Salud Community Health Program, with funding from

Partners In Health.

References

1. White Hughto JM, Reisner SL, Pachankis JE. Transgender stigma and health: a critical review of

stigma determinants, mechanisms, and interventions. Soc Sci Med 2015;147:222–231; doi:

10.1016/j.socscimed.2015.11.010.

2. Safer JD, Tangpricha V. Care of the transgender patient. Annals of Internal Medicine

2019;171(1):ITC1-ITC16; doi: 10.7326/AITC201907020.

3.   Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-

sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol

2013;169(4):471–478; doi: 10.1530/EJE-13-0493.

4.   Reisner SL, Poteat T, Keatley J, et al. Global health burden and needs of transgender populations: a

review. Lancet Lond Engl 2016;388(10042):412–436; doi: 10.1016/S0140-6736(16)00684-X.

5.   TvT Project. Trans day of remembrance (TDoR) 2018 press release. TvT Project; Berlin, Germany;

2018. Available from: https://transrespect.org/en/tmm-update-tdor-2018/ [Last accessed: September

27, 2021].

6.   Perez-Brumer A, Silva-Santisteban A. COVID-19 policies can perpetuate violence against

transgender communities: insights from Peru. AIDS Behav 2020;24(9):2477–2479; doi:

10.1007/s10461-020-02889-z.

7.   UNAIDS. The injustices faced by transgender women in Peru. UNAIDS: Geneva, Switzerland; 2018.

Available from: https://www.unaids.org/en/resources/presscentre/featurestories/2018/april/injustices-

faced-by-transgender-women-in-Peru [Last accessed: November 5, 2022].

8.   Malta M, Cardoso R, Montenegro L, et al. Sexual and gender minorities rights in Latin America and

the Caribbean: a multi-country evaluation. BMC Int Health Hum Rights 2019;19(1):31; doi:

10.1186/s12914-019-0217-3.

9.   Malta M, Silva AB, LeGrand S, et al. HIV/AIDS, human rights, and transgender people in Latin

America. Lancet Public Health 2019;4(6):e279; doi: 10.1016/S2468-2667(19)30082-9.

10. Clark J, Perez-Brumer A, Reisner S, et al. Social network organization, structure, and patterns of

influence within a community of transgender women in Lima, Peru: implications for biomedical HIV

prevention. AIDS Behav 2020;24(1):233–245; doi: 10.1007/s10461-019-02506-8.

11. Silva-Santisteban A, Raymond HF, Salazar X, et al. Understanding the HIV/AIDS epidemic in

transgender women of Lima, Peru: results from a sero-epidemiologic study using respondent driven

sampling. AIDS Behav 2012;16(4):872–881; doi: 10.1007/s10461-011-0053-5.

12. The night is another country: impunity and violence against transgender women human rights

defenders in Latin America. Red Latinoamericana y del Caribe de Personas Trans [Latin American

and Caribbean Network of Trans People] (REDLACTRANS): Buenos Aires Argentina; 2012.

Available from: http://redlactrans.org.ar/site/wp-content/uploads/2013/05/Violencia-e-impunidad-

English1.pdf. [Last accessed: October 27, 2021].

13. Salazar X, Núnez-Curto A, Villayzán Aguilar J, et al. Confluent paths: research and community

participation to protect the right to health among transgender women in Peru. Glob Public Health

2019;14(6–7):954–962; doi: 10.1080/17441692.2019.1599982.

14. John Snow, Inc., PAHO. Blueprint for the provision of comprehensive care for trans persons and their

communities in the Caribbean and other anglophone countries. World Professional Association for

Transgender Health: East Dundee, Illinois, USA; 2014;88. Available from:

https://www.paho.org/en/file/39610/download?token = S56Unhmm. [Last accessed: October 27,

2021].

15. Ortiz-Martínez Y, Ríos-González CM. Need for more research on and health interventions for

transgender people. Sex Health 2017;14(2):196–197; doi: 10.1071/SH16148.

16. Parker R, Aggleton P, Perez-Brumer AG. The trouble with 'categories': rethinking men who have sex

with men, transgender and their equivalents in HIV prevention and health promotion. Glob Public

Health 2016;11(7–8):819–823; doi: 10.1080/17441692.2016.1185138.

17. Poteat TC, Keatley J, Wilcher R, et al. Evidence for action: a call for the global HIV response to

address the needs of transgender populations. J Int AIDS Soc 2016;19(3Suppl 2):21193; doi:

10.7448/IAS.19.3.21193.

18. Counting trans populations. UCSF Prevention Science Department of Medicine: San Francisco, CA,

USA; 2022. Available from: https://prevention.ucsf.edu/transhealth/education/data-recs-summary

[Last accessed: October 27, 2021].

19. Konda KA, Torres TS, Mariño G, et al. Factors associated with long□term HIV pre□exposure

prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru:

results from the ImPrEP study. J Int AIDS Soc 2022;25(Suppl 5):e25974; doi: 10.1002/jia2.25974.

20. World Health Organization. Global tuberculosis report 2020. World Health Organization: Geneva,

Switzerland; 2020. Available from: https://www.who.int/publications-detail-redirect/9789240013131

[Last accessed: October 27, 2021]

21. Willie B, Hakim AJ, Badman SG, et al. High prevalence of pulmonary tuberculosis among female sex

workers, men who have sex with men, and transgender women in Papua New Guinea. Trop Med

Health 2021;49(1):4; doi: 10.1186/s41182-020-00293-w.

22. Pollock L, Silva-Santisteban A, Sevelius J, et al. "You should build yourself up as a whole product":

transgender female identity in Lima, Peru. Glob Public Health 2016;11(7–8):981–993; doi:

10.1080/17441692.2016.1167932.

23. Lee Badgett M, Baker K, Conron KJ, et al. Best practices for asking questions to identify transgender

and other gender minority respondents on population-based surveys (GenIUSS). UCLA School of

Law Williams Institute: Los Angeles, CA, USA; 2014. Available from:

https://williamsinstitute.law.ucla.edu/publications/geniuss-trans-pop-based-survey/ [Last accessed:

October 27, 2021]

24. Meerwijk EL, Sevelius JM. Transgender population size in the United States: a meta-regression of

population-based probability samples. Am J Public Health 2017;107(2): e1-e8; doi:

10.2105/AJPH.2016.303578.

25. M Pun. Situación de la epidemia de VIH en Peru. [Situation of the HIV epidemic in Peru]. Red

Nacional de Epidemiologia [National Network of Epidemiology]: Lima, Peru; 2015. Available from:

https://web.kamihq.com/web/viewer.html?source = extension_pdfhandler&file =

https%3A%2F%2Fwww.minsa.gob.pe%2Fportada%2FEspeciales%2F2015%2Fvih%2Fmatcom%2F

Situacion-Epidemiologica-VIH-2015.pdf [Last accessed: October 27, 2021]

26. ¿Qué es el VIH y SIDA? Plataforma digital única del Estado Peruano [What is HIV and AIDS?

Single digital platform of the Peruvian State]. Presidencia del Consejo de Ministros [Presidency of the

Counsil of Ministers]: Lima, Peru; 2022. Available from: https://www.gob.pe/16439-que-es-el-vih-y-

sida [Last accessed: October 10, 2022].

27. Lee SW, Deiss RG, Segura ER, et al. A cross-sectional study of low HIV testing frequency and high-

risk behaviour among men who have sex with men and transgender women in Lima, Peru. BMC

Public Health 2015;15:408; doi: 10.1186/s12889-015-1730-5.

28. Dirección General de Intervenciones Estratégicas en Salud Pública del Ministerio de Salud [General

Directorate of Strategic Interventions in Public Health of the Ministry of Health]. Ministerial

resolution N° 980-2016-MINSA. MINSA: Lima, Peru; 2016. Available from:

https://www.gob.pe/institucion/minsa/normas-legales/191440-980-2016-minsa [Last accessed:

October 27, 2021].

29. Longino A, Montano MA, Sanchez H, et al. Increasing PrEP uptake and adherence among MSM and

TW sex workers in Lima, Peru: what and whom do different patients trust? AIDS Care

2020;32(2):255–260; doi: 10.1080/09540121.2019.1634787.

30. Fundação Osvaldo Cruz, Ministry of Health of Brazil, University Caetano Heredia, Condesa Clinic,

UNITAID. ImPrEP Project. Fundação Osvaldo Cruz: Rio de Janeiro, Brazil. Available from:

http://imprep.org/Peru/o-projeto-imprep/ [Last accessed: October 27, 2021].

31. Prep Vih. [PrEP HIV]. Mercado Libre: Lima, Peru. Available from:

https://listado.mercadolibre.com.pe/prep-vih [Last accessed: January 28, 2022].

32. PrEPWatch. A snapshot of PrEP scale-up, registration and resources for Peru. AVAC: New York,

NY, USA; 2021. Available from: https://www.prepwatch.org/countries/Peru/ [Last accessed: October

27, 2021].

33. Delcore AL, Scargglioni C. A. La lucha de las mujeres trans en tiempos de pandemia. [The fight of

transgender women in times of pandemic]. El Comercio Peru: Lima, Peru; 2020. Available from:

https://especiales.elcomercio.pe/?q = especiales/mujeres-trans-en-tiempos-de-pandemia-

ecpm/index.html [Last accessed: October 27, 2021].

34. Chow JY, Konda KA, Borquez A, et al. Peru's HIV care continuum among men who have sex with

men and transgender women: opportunities to optimize treatment and prevention. Int J STD AIDS

2016;27(12):1039–1048; doi: 10.1177/0956462416645727.

35. United States Department of State, Bureau of Democracy, Human Rights and Labor. Peru 2016

human rights report. United States Department of State: Washington, DC, USA; 2016. Available

from: https://www.state.gov/wp-content/uploads/2019/01/Peru-1.pdf [Last accessed: October 27,

2021].

36. Perez-Brumer AG, Reisner SL, McLean SA, et al. Leveraging social capital: multilevel stigma,

associated HIV vulnerabilities, and social resilience strategies among transgender women in Lima,

Peru. J Int AIDS Soc 2017;20(1):21462; doi: 10.7448/IAS.20.1.21462.

37. Reisner SL, Perez-Brumer AG, McLean SA, et al. Perceived barriers and facilitators to integrating

HIV prevention and treatment with cross- sex hormone therapy for transgender women in Lima, Peru.

AIDS Behav 2017;21(12):3299–3311; doi: 10.1007/s10461-017-1768-8.

38. Chávez Yacila R. Ni empleadas ni ciudadanas: no hay tregua para las mujeres trans. [Neither

employees nor citizens: no truce for trans women]. Ojo Público: Lima, Peru; 2021. Available from:

https://ojo-publico.com/2979/no-hay-tregua-para-las-mujeres-trans-en-Peru [Last accessed: October

27, 2021].

39. Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention

strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian

populations. Int J STD AIDS 2011;22(5):256–262; doi: 10.1258/ijsa.2009.009255.

40. Collave Garcia Y. La nueva opción para prevenir el VIH que se probó en Peru (y que demostró ser

eficaz). [The new option to prevent HIV that was proven in Peru (and that was demonstrated to be

efficacious)]. El Comercio Peru: Lima, Peru; 2021. Available from:

412  https://elcomercio.pe/tecnologia/ciencias/vih-sida-cabotegravir-la-nueva-opcion-para-prevenir-el-vih-

413  que-se-probo-en-Peru-y-que-demostro-ser-eficaz-noticia/ [Last accessed: October 27, 2021].

414 41. National Institutes of Health. Long-acting injectable form of HIV prevention outperforms daily pill in

415  NIH study. National Institutes of Health: Bethesda, MD, USA; 2020. Available from:

416  https://www.nih.gov/news-events/news-releases/long-acting-injectable-form-hiv-prevention-

417  outperforms-daily-pill-nih-study [Last accessed: October 27, 2021].

418 42. Office of the Commissioner, U.S. Food and Drug Administration. FDA Approves First Injectable

419  Treatment for HIV Pre-Exposure Prevention. FDA: Silver Spring, MD, USA; 2021. Available from:

420  https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-

421  pre-exposure-prevention [Last accessed: January 28, 2022].

422   **Table 1: Socio-demographic Characteristics of a Sample of Transgender Women in Lima, Peru (N = 301)**

Age	Mean ± Standard Deviation n (%)
Mean	32.4 ± 8.44
Range	18 - 64
< 27 years	73 (24.3%)
27-35 years	141 (46.8%)
> 35 years	87 (28.9%)
Education	
≤ Primary	19 (6.3%)
Secondary	172 (57.1%)
> Primary	110 (36.5%)
Hometown	
Lima	140 (46.5%)
Other departments	161 (53.5%)
Employment	
Currently Working	238 (79.1%)
(Of those who responded yes)	
Work for a business [a]	59 (19.6%)
Work independently [a]	50 (16.6%)
Sex work [a]	145 (48.2%)
Gender identity	
Woman	46 (15.3%)
Trans or transgender	176 (58.5%)
Transsexual	25 (8.3%)
Transformista	27 (9.0%)
Travesti	21 (7.0%)
Other	6 (2.0%)

423   [a] *non-exclusive response options*

424   **Table 2: Health and Service Utilization among a Sample of Transgender Women in Lima, Peru (N = 301)**

Insurance	n (%)
No insurance	106 (35.2%)
Seguro Integral de Salud (SIS) [a]	162 (53.8%)
Seguro Social de Salud (EsSalud) [b]	21 (7.0%)
Private insurance	11 (3.7%)
Entidades Prestadoras de Salud (EPS) [c]	1 (0.3%)
Clinic Attendance	
Attended health clinic	241 (80.1%)
(Of those who responded yes)	
Public	201 (83.4%)
Private	40 (16.6%)
Illness	
Reported suffering from illness	62 (20.6%)
Human Immunodeficiency Virus (HIV) Testing	
In the last 6 months	139 (46.2%)
6-12 months ago	34 (11.3%)
Over a year ago	117 (38.9%)
Never	11 (3.7%)
Tuberculosis (TB) Testing	
In the last 6 months	46 (15.3%)
6-12 months ago	19 (6.3%)
Over a year ago	126 (41.9%)
Never	110 (36.5%)
Pre-exposure prophylaxis (PrEP)	
Heard of PrEP	181 (60.1%)
(Of those who responded yes)	
Interested in PrEP	101 (55.8%)
Ever taken PrEP	38 (21.0%)
Gender Affirming Care	
Undergone gender affirming procedure	275 (91.4%)
(Of those who responded yes)	
Hormone or silicone injection	225 (81.8%)
Sex reassignment surgery (SRS)	1 (0.4%)
Surgical procedure without SRS	40 (14.6%)
Other	9 (3.3%)

439   [a] *Seguro Integral de Salud* [subsidized public health insurance]
440   [b] *Seguro Social de Salud* [contributory public social health insurance]
441   [c] *Entidades Prestadoras de Salud* [supplementary health insurance covering private health providers]

Table 3: Healthcare Utilization and Access among a Sample of Transgender Women in Lima, Peru - Prevalence Ratios and 95% Confidence Intervals

	N = 301	Uninsured		Illness		Clinic Attendance		Tuberculosis (TB) Testing		Human Immunodeficiency Virus (HIV) Testing		Pre-exposure prophylaxis (PrEP) Use	
		Unadjusted	Adjusted [a]	Unadjusted	Adjusted [a]	Unadjusted	Adjusted [a]	Unadjusted	Adjusted [a]	Unadjusted	Adjusted [a]	Unadjusted	Adjusted [a]
Age Group (Reference: < 27 years)													
27-35	n = 141 (46.8%)	0.62 (0.43, 0.89)	0.62 (0.43, 0.90)	1.29 (0.63, 2.64)	1.13 (0.55, 2.32)	1.10 (0.93, 1.29)	1.08 (0.91, 1.27)	0.69 (0.39, 1.24)	0.57 (0.31, 1.05)	1.02 (0.77, 1.36)	0.93 (0.71, 1.23)	0.58 (0.30, 1.13)	0.70 (0.35, 1.37)
> 35	n = 87 (28.9%)	0.63 (0.42, 0.96)	0.67 (0.43, 1.04)	2.32 (1.16, 4.66)	1.58 (0.78, 3.22)	1.19 (1.00, 1.40)	1.15 (0.97, 1.36)	0.27 (0.11, 0.71)	0.27 (0.10, 0.72)	0.62 (0.42, 0.93)	0.68 (0.45, 1.01)	0.79 (0.37, 1.66)	1.05 (0.47, 2.34)
Education (Reference: > Secondary)													
≤ Primary	n = 19 (6.3%)	1.75 (1.06, 2.90)	1.77 (1.04, 3.03)	2.59 (1.13, 5.93)	2.61 (1.07, 6.40)	1.05 (0.84, 1.32)	1.05 (0.84, 1.32)	0.26 (0.04, 1.78)	0.29 (0.05, 1.89)	0.65 (0.36, 1.20)	0.71 (0.40, 1.24)	0.55 (0.08, 3.69)	0.44 (0.08, 2.54)
Secondary	n = 172 (57.1%)	1.09 (0.76, 1.56)	1.07 (0.73, 1.56)	1.79 (1.00, 3.21)	1.50 (0.81, 2.78)	1.03 (0.91, 1.16)	1.00 (0.88, 1.14)	0.56 (0.32, 0.98)	0.61 (0.35, 1.06)	0.66 (0.51, 0.85)	0.70 (0.54, 0.90)	1.16 (0.64, 2.10)	1.20 (0.61, 2.38)
Department of Origin (Reference: Departments other than Lima)													
Lima	n = 140 (46.5%)	0.86 (0.62, 1.19)	0.92 (0.65, 1.29)	1.34 (0.83, 2.15)	1.13 (0.70, 1.84)	1.00 (0.89, 1.13)	0.98 (0.87, 1.10)	0.67 (0.37, 1.20)	0.64 (0.36, 1.15)	0.79 (0.61, 1.03)	0.80 (0.62, 1.04)	0.99 (0.55, 1.78)	0.68 (0.36, 1.28)
Employment (Reference: Unemployed)													
Employed	n = 238 (79.1%)	1.22 (0.78 1.91)	1.14 (0.69, 1.87)	0.37 (0.23, 0.58)	0.48 (0.27, 0.85)	0.86 (0.77, 0.96)	0.88 (0.76, 1.02)	1.04 (0.51, 2.12)	1.01 (0.47, 2.18)	1.06 (0.76, 1.47)	0.95 (0.66, 1.37)	0.68 (0.36, 1.28)	0.52 (0.21, 1.27)
Sex Work (Reference: Not engaged in sex work)													
Sex work	n = 145 (48.2%)	1.13 (0.81, 1.56)	0.90 (0.61, 1.33)	0.48 (0.29, 0.81)	0.75 (0.39, 1.43)	0.92 (0.82, 1.04)	1.00 (0.87 1.15)	0.99 (0.57, 1.73)	0.74 (0.38, 1.44)	1.06 (0.82, 1.36)	0.98 (0.73, 1.31)	1.00 (0.56, 1.79)	1.31 (0.55, 3.09)
Gender Identity (Reference: Trans or transgender)													
Woman	n = 46 (15.3%)	1.06 (0.70, 1.62)	1.09 (0.72, 1.66)	0.69 (0.31, 1.55)	0.77 (0.35, 1.69)	0.93 (0.77, 1.12)	0.93 (0.77, 1.12)	1.64 (0.85, 3.17)	1.69 (0.89, 3.22)	1.55 (1.19, 2.02)	1.49 (1.16, 1.91)	1.94 (1.00, 3.76)	2.36 (1.15, 4.80)
Trans-sexual	n = 25 (8.3%)	0.72 (0.35, 1.47)	0.75 (0.36, 1.57)	1.11 (0.48, 2.55)	0.94 (0.44, 2.02)	1.07 (0.90, 1.28)	1.05 (0.88, 1.24)	1.57 (0.66, 3.71)	1.66 (0.72, 3.80)	1.09 (0.69, 1.72)	1.09 (0.69, 1.73)	1.85 (0.74, 4.64)	1.62 (0.66, 4.02)
Transformista	n = 27 (9.0%)	0.59 (0.21, 1.64)	0.62 (0.23, 1.67)	1.45 (0.60, 3.52)	1.01 (0.39, 2.59)	1.15 (0.98, 1.35)	1.08 (0.91, 1.27)	1.03 (0.27, 3.92)	1.09 (0.33, 3.60)	0.98 (0.52, 1.83)	0.98 (0.49, 1.94)	undefined	undefined
Travesti	n = 21 (7.0%)	0.81 (0.38, 1.73)	0.76 (0.38, 1.53)	1.80 (0.88, 3.66)	1.21 (0.60, 2.44)	1.02 (0.81, 1.28)	0.99 (0.78, 1.22)	undefined	undefined	0.40 (0.14, 1.14)	0.50 (0.17, 1.44)	0.67 (0.10, 4.46)	0.51 (0.09, 2.90)
Other	n = 6 (2.0%)	1.37 (0.50, 3.74)	1.15 (0.45, 2.90)	undefined	undefined	0.62 (0.23, 1.65)	0.62 (0.24, 1.61)	1.80 (0.32, 10.27)	1.49 (0.35, 6.37)	1.14 (0.42, 3.08)	1.00 (0.38, 2.70)	6.00 (3.93, 9.16)	5.64 (2.75, 11.58)

[a] *Covariates included age group, education level (primary or less, secondary, or higher than secondary), department of origin (Lima or other department of origin), current employment (yes/no), sex work (yes/no), and gender identity subgroup*